000274419 001__ 274419
000274419 005__ 20240229154933.0
000274419 0247_ $$2doi$$a10.1002/cjp2.311
000274419 0247_ $$2pmid$$apmid:36948887
000274419 0247_ $$2altmetric$$aaltmetric:144212573
000274419 037__ $$aDKFZ-2023-00586
000274419 041__ $$aEnglish
000274419 082__ $$a610
000274419 1001_ $$00000-0002-6615-2037$$aKöbel, Martin$$b0
000274419 245__ $$ap53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study.
000274419 260__ $$aChichester$$bWiley$$c2023
000274419 3367_ $$2DRIVER$$aarticle
000274419 3367_ $$2DataCite$$aOutput Types/Journal article
000274419 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1681199148_5540
000274419 3367_ $$2BibTeX$$aARTICLE
000274419 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000274419 3367_ $$00$$2EndNote$$aJournal Article
000274419 500__ $$a2023 May;9(3):208-222
000274419 520__ $$aOur objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC], and clear cell carcinoma [CCC]) using a large multi-institutional cohort from the Ovarian Tumor Tissue Analysis (OTTA) consortium. p53 expression was assessed on 6,678 cases represented on tissue microarrays from 25 participating OTTA study sites using a previously validated immunohistochemical (IHC) assay as a surrogate for the presence and functional effect of TP53 mutations. Three abnormal expression patterns (overexpression, complete absence, and cytoplasmic) and the normal (wild type) pattern were recorded. Survival analyses were performed by histotype. The frequency of abnormal p53 expression was 93.4% (4,630/4,957) in HGSC compared to 11.9% (116/973) in EC and 11.5% (86/748) in CCC. In HGSC, there were no differences in overall survival across the abnormal p53 expression patterns. However, in EC and CCC, abnormal p53 expression was associated with an increased risk of death for women diagnosed with EC in multivariate analysis compared to normal p53 as the reference (hazard ratio [HR] = 2.18, 95% confidence interval [CI] 1.36-3.47, p = 0.0011) and with CCC (HR = 1.57, 95% CI 1.11-2.22, p = 0.012). Abnormal p53 was also associated with shorter overall survival in The International Federation of Gynecology and Obstetrics stage I/II EC and CCC. Our study provides further evidence that functional groups of TP53 mutations assessed by abnormal surrogate p53 IHC patterns are not associated with survival in HGSC. In contrast, we validate that abnormal p53 IHC is a strong independent prognostic marker for EC and demonstrate for the first time an independent prognostic association of abnormal p53 IHC with overall survival in patients with CCC.
000274419 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000274419 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000274419 650_7 $$2Other$$aTP53
000274419 650_7 $$2Other$$aclear cell
000274419 650_7 $$2Other$$aendometrioid
000274419 650_7 $$2Other$$ahigh-grade serous carcinoma
000274419 650_7 $$2Other$$aovarian cancer
000274419 650_7 $$2Other$$ap53
000274419 650_7 $$2Other$$aprognosis
000274419 7001_ $$aKang, Eun-Young$$b1
000274419 7001_ $$00000-0002-3072-2616$$aWeir, Ashley$$b2
000274419 7001_ $$aRambau, Peter F$$b3
000274419 7001_ $$aLee, Cheng-Han$$b4
000274419 7001_ $$aNelson, Gregg S$$b5
000274419 7001_ $$aGhatage, Prafull$$b6
000274419 7001_ $$aMeagher, Nicola S$$b7
000274419 7001_ $$aRiggan, Marjorie J$$b8
000274419 7001_ $$aAlsop, Jennifer$$b9
000274419 7001_ $$00000-0003-1639-5003$$aAnglesio, Michael S$$b10
000274419 7001_ $$aBeckmann, Matthias W$$b11
000274419 7001_ $$aBisinotto, Christiani$$b12
000274419 7001_ $$aBoisen, Michelle$$b13
000274419 7001_ $$aBoros, Jessica$$b14
000274419 7001_ $$aBrand, Alison H$$b15
000274419 7001_ $$aBrooks-Wilson, Angela$$b16
000274419 7001_ $$aCarney, Michael E$$b17
000274419 7001_ $$aCoulson, Penny$$b18
000274419 7001_ $$aCourtney-Brooks, Madeleine$$b19
000274419 7001_ $$aCushing-Haugen, Kara L$$b20
000274419 7001_ $$aCybulski, Cezary$$b21
000274419 7001_ $$aDeen, Suha$$b22
000274419 7001_ $$aEl-Bahrawy, Mona A$$b23
000274419 7001_ $$aElishaev, Esther$$b24
000274419 7001_ $$00000-0003-0315-1229$$aErber, Ramona$$b25
000274419 7001_ $$aFereday, Sian$$b26
000274419 7001_ $$aGroup, AOCS$$b27$$eCollaboration Author
000274419 7001_ $$aFischer, Anna$$b28
000274419 7001_ $$aGayther, Simon A$$b29
000274419 7001_ $$aBarquin-Garcia, Arantzazu$$b30
000274419 7001_ $$aGentry-Maharaj, Aleksandra$$b31
000274419 7001_ $$00000-0001-7889-8250$$aGilks, C Blake$$b32
000274419 7001_ $$aGronwald, Helena$$b33
000274419 7001_ $$aGrube, Marcel$$b34
000274419 7001_ $$aHarnett, Paul R$$b35
000274419 7001_ $$aHarris, Holly R$$b36
000274419 7001_ $$aHartkopf, Andreas D$$b37
000274419 7001_ $$aHartmann, Arndt$$b38
000274419 7001_ $$aHein, Alexander$$b39
000274419 7001_ $$aHendley, Joy$$b40
000274419 7001_ $$aHernandez, Brenda Y$$b41
000274419 7001_ $$aHuang, Yajue$$b42
000274419 7001_ $$aJakubowska, Anna$$b43
000274419 7001_ $$aJimenez-Linan, Mercedes$$b44
000274419 7001_ $$aJones, Michael E$$b45
000274419 7001_ $$aKennedy, Catherine J$$b46
000274419 7001_ $$aKluz, Tomasz$$b47
000274419 7001_ $$aKoziak, Jennifer M$$b48
000274419 7001_ $$aLesnock, Jaime$$b49
000274419 7001_ $$aLester, Jenny$$b50
000274419 7001_ $$aLubiński, Jan$$b51
000274419 7001_ $$aLongacre, Teri A$$b52
000274419 7001_ $$aLycke, Maria$$b53
000274419 7001_ $$aMateoiu, Constantina$$b54
000274419 7001_ $$aMcCauley, Bryan M$$b55
000274419 7001_ $$aMcGuire, Valerie$$b56
000274419 7001_ $$aNey, Britta$$b57
000274419 7001_ $$aOlawaiye, Alexander$$b58
000274419 7001_ $$aOrsulic, Sandra$$b59
000274419 7001_ $$aOsorio, Ana$$b60
000274419 7001_ $$aPaz-Ares, Luis$$b61
000274419 7001_ $$aRamón Y Cajal, Teresa$$b62
000274419 7001_ $$aRothstein, Joseph H$$b63
000274419 7001_ $$aRuebner, Matthias$$b64
000274419 7001_ $$aSchoemaker, Minouk J$$b65
000274419 7001_ $$aShah, Mitul$$b66
000274419 7001_ $$aSharma, Raghwa$$b67
000274419 7001_ $$aSherman, Mark E$$b68
000274419 7001_ $$00000-0001-5131-9618$$aShvetsov, Yurii B$$b69
000274419 7001_ $$aSingh, Naveena$$b70
000274419 7001_ $$aSteed, Helen$$b71
000274419 7001_ $$aStorr, Sarah J$$b72
000274419 7001_ $$aTalhouk, Aline$$b73
000274419 7001_ $$aTraficante, Nadia$$b74
000274419 7001_ $$aWang, Chen$$b75
000274419 7001_ $$aWhittemore, Alice S$$b76
000274419 7001_ $$aWidschwendter, Martin$$b77
000274419 7001_ $$aWilkens, Lynne R$$b78
000274419 7001_ $$aWinham, Stacey J$$b79
000274419 7001_ $$aBenitez, Javier$$b80
000274419 7001_ $$aBerchuck, Andrew$$b81
000274419 7001_ $$aBowtell, David D$$b82
000274419 7001_ $$aCandido Dos Reis, Francisco J$$b83
000274419 7001_ $$00000-0002-7773-4155$$aCampbell, Ian$$b84
000274419 7001_ $$aCook, Linda S$$b85
000274419 7001_ $$aDeFazio, Anna$$b86
000274419 7001_ $$aDoherty, Jennifer A$$b87
000274419 7001_ $$aFasching, Peter A$$b88
000274419 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée T$$b89$$udkfz
000274419 7001_ $$aGarcía, María J$$b90
000274419 7001_ $$aGoodman, Marc T$$b91
000274419 7001_ $$aGoode, Ellen L$$b92
000274419 7001_ $$aGronwald, Jacek$$b93
000274419 7001_ $$00000-0003-4934-3322$$aHuntsman, David G$$b94
000274419 7001_ $$aKarlan, Beth Y$$b95
000274419 7001_ $$aKelemen, Linda E$$b96
000274419 7001_ $$aKommoss, Stefan$$b97
000274419 7001_ $$aLe, Nhu D$$b98
000274419 7001_ $$aMartin, Stewart G$$b99
000274419 7001_ $$aMenon, Usha$$b100
000274419 7001_ $$aModugno, Francesmary$$b101
000274419 7001_ $$aPharoah, Paul Dp$$b102
000274419 7001_ $$aSchildkraut, Joellen M$$b103
000274419 7001_ $$aSieh, Weiva$$b104
000274419 7001_ $$aStaebler, Annette$$b105
000274419 7001_ $$aSundfeldt, Karin$$b106
000274419 7001_ $$aSwerdlow, Anthony J$$b107
000274419 7001_ $$aRamus, Susan J$$b108
000274419 7001_ $$aBrenton, James D$$b109
000274419 773__ $$0PERI:(DE-600)2814357-7$$a10.1002/cjp2.311$$gp. cjp2.311$$n3$$p208-222$$tThe journal of pathology: clinical research$$v9$$x2056-4538$$y2023
000274419 909CO $$ooai:inrepo02.dkfz.de:274419$$pVDB
000274419 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b89$$kDKFZ
000274419 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000274419 9141_ $$y2023
000274419 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-04-16T15:13:41Z
000274419 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-04-16T15:13:41Z
000274419 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2021-04-16T15:13:41Z
000274419 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-18
000274419 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-18
000274419 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2022-11-18
000274419 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2022-11-18
000274419 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PATHOL CLIN RES : 2022$$d2023-10-26
000274419 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-26
000274419 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-26
000274419 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-26
000274419 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-26
000274419 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-26
000274419 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-26
000274419 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-26
000274419 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000274419 980__ $$ajournal
000274419 980__ $$aVDB
000274419 980__ $$aI:(DE-He78)C020-20160331
000274419 980__ $$aUNRESTRICTED